Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 6
1964 6
1966 1
1967 6
1968 8
1969 12
1970 8
1971 8
1972 14
1973 7
1974 17
1975 14
1976 8
1977 12
1978 9
1979 9
1980 9
1981 8
1982 9
1983 15
1984 8
1985 10
1986 9
1987 5
1988 15
1989 34
1990 34
1991 30
1992 25
1993 31
1994 36
1995 26
1996 40
1997 27
1998 28
1999 31
2000 36
2001 37
2002 47
2003 52
2004 36
2005 33
2006 31
2007 43
2008 31
2009 39
2010 47
2011 53
2012 66
2013 80
2014 78
2015 77
2016 66
2017 55
2018 62
2019 46
2020 73
2021 82
2022 57
2023 66
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,766 results

Results by year

Filters applied: . Clear all
Page 1
Gaucher Disease for Hematologists.
Özdemir GN, Gündüz E. Özdemir GN, et al. Turk J Haematol. 2022 Jun 1;39(2):136-139. doi: 10.4274/tjh.galenos.2021.2021.0683. Epub 2022 Apr 20. Turk J Haematol. 2022. PMID: 35439918 Free PMC article. Review.
Early diagnosis is very important for starting proper treatment and preventing complications. Splenomegaly, anemia, and thrombocytopenia are the most common findings in GD and so most patients are initially referred to hematologists. ...
Early diagnosis is very important for starting proper treatment and preventing complications. Splenomegaly, anemia, and thrombocytope …
Splenomegaly: investigation, diagnosis and management.
Pozo AL, Godfrey EM, Bowles KM. Pozo AL, et al. Blood Rev. 2009 May;23(3):105-11. doi: 10.1016/j.blre.2008.10.001. Epub 2008 Dec 4. Blood Rev. 2009. PMID: 19062140 Review.
Splenomegaly is a feature of a broad range of diseases, and presents to clinicians in many fields. This review examines the aetiology of splenomegaly in the developed world, and describes a logical approach to the patient with splenomegaly. ...
Splenomegaly is a feature of a broad range of diseases, and presents to clinicians in many fields. This review examines the aetiology …
Non-cirrhotic portal hypertension - diagnosis and management.
Khanna R, Sarin SK. Khanna R, et al. J Hepatol. 2014 Feb;60(2):421-41. doi: 10.1016/j.jhep.2013.08.013. Epub 2013 Aug 23. J Hepatol. 2014. PMID: 23978714 Free article. Review.
Persistent growth failure, symptomatic and recurrent hepatic encephalopathy, impaired quality of life or massive splenomegaly that interferes with daily activities are other surgical indications. ...
Persistent growth failure, symptomatic and recurrent hepatic encephalopathy, impaired quality of life or massive splenomegaly that in …
Infectious Mononucleosis: An Updated Review.
Leung AKC, Lam JM, Barankin B. Leung AKC, et al. Curr Pediatr Rev. 2024;20(3):305-322. doi: 10.2174/1573396320666230801091558. Curr Pediatr Rev. 2024. PMID: 37526456 Review.
Periorbital and/or palpebral edema, typically bilateral, occurs in one-third of patients. Splenomegaly and hepatomegaly occur in approximately 50% and 10% of cases, respectively. ...Patients should be advised to avoid contact sports or strenuous exercise for 8 weeks or whi …
Periorbital and/or palpebral edema, typically bilateral, occurs in one-third of patients. Splenomegaly and hepatomegaly occur in appr …
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T. Marchetti M, et al. Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. Lancet Haematol. 2022. PMID: 35358444 Review.
The expert panel recommended that patients with polycythaemia vera who are younger than 60 years and have not had previous thrombotic events should start cytoreductive drug therapy if at least one of the following criteria are fulfilled: strictly defined intolerance to phlebotomy …
The expert panel recommended that patients with polycythaemia vera who are younger than 60 years and have not had previous thrombotic events …
Splenic irradiation for splenomegaly: A systematic review.
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Zaorsky NG, et al. Cancer Treat Rev. 2017 Feb;53:47-52. doi: 10.1016/j.ctrv.2016.11.016. Epub 2016 Dec 22. Cancer Treat Rev. 2017. PMID: 28063304 Free PMC article. Review.
Splenic irradiation (SI) is a palliative treatment option for symptomatic splenomegaly (i.e. for pain, early satiety, pancytopenia from sequestration) secondary to hematologic malignancies and disorders. ...In summary, SI is generally a safe and efficacious method for trea …
Splenic irradiation (SI) is a palliative treatment option for symptomatic splenomegaly (i.e. for pain, early satiety, pancytopenia fr …
[Myelofibrosis: A review].
Genthon A, Killian M, Mertz P, Cathebras P, Gimenez De Mestral S, Guyotat D, Chalayer E. Genthon A, et al. Rev Med Interne. 2021 Feb;42(2):101-109. doi: 10.1016/j.revmed.2020.08.018. Epub 2020 Nov 23. Rev Med Interne. 2021. PMID: 33243417 Review. French.
It is characterized by stem cell-derived clonal proliferation that is often, but not always, accompanied by somatic mutations, which are classified into driver mutations (JAK2, CALR, or MPL), subclonal mutations and fibrosis on bone marrow biopsy. Myelofibrosis commonly demonstra …
It is characterized by stem cell-derived clonal proliferation that is often, but not always, accompanied by somatic mutations, which are cla …
β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J. Asadov C, et al. Int J Hematol. 2018 Jul;108(1):5-21. doi: 10.1007/s12185-018-2411-9. Epub 2018 Jan 29. Int J Hematol. 2018. PMID: 29380178 Review.
Ineffective erythropoiesis, chronic anemia, and iron overload contribute to the clinical complications of thalassemia intermedia through stepwise pathophysiological mechanisms. These complications, including splenomegaly, extramedullary erythropoiesis, iron accumulation, l …
Ineffective erythropoiesis, chronic anemia, and iron overload contribute to the clinical complications of thalassemia intermedia through ste …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease; in case of intermediate-1 disease, ruxolitinib is recommended in highly symptomatic splenomegaly. ...
Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease …
1,766 results